Read if you want one stock you can retire on

Search

Member
Joined
Jan 19, 2005
Messages
3,247
Tokens
8K out - Item 8.01 Other Business Information
Business Update for Predictive Laboratories and Predictive Analytics
On May 7, 2021, the Company entered into a strategic development agreement (the "Agreement") with Nebula Genomics ("Nebula"). Under the terms of the Agreement, the Company may offer Nebula products to its customers, including 30x whole genome sequencing testing, analytical tools, and other products and services, which are fulfilled by Nebula. The Agreement includes a revenue sharing arrangement between the Company and Nebula.
Nebula has agreed to provide the Company with technologies and services to assist in Direct-To-Consumer ("DTC") and clinical diagnostic markets including privacy technologies, such as blockchain, and analytical tools. The Company and Nebula intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. These development activities are expected to be governed by joint scientific and medical advisory boards with representation from both companies.


On June 11, 2021, the Company entered into a strategic collaboration and development agreement (the "Inherent Agreement") with Inherent Biosciences, Inc. ("Inherent"). Under the terms of the Inherent Agreement, the Company may offer Inherent's commercial epigenetic based Sperm Biological Age product to its customers. Additionally, the Inherent Agreement contemplates the Company offering additional Inherent products as they become commercially available. These additional products may include:


Clinical Validation Phase
- Male Infertility Diagnostic (MFI)

Proof-of-Concept Phase
- Arthritis
- Premature Birth
- Autism (buccal swab parents/child)
- Autism (germline sperm)
- Hypospadias
- Fetal Heart Disease


Discovery Phase
- Developmental Abnormalities
- Endometriosis diagnostics
The Company and Inherent have revenue sharing provisions in the Inherent Agreement.
Inherent has agreed to provide Predictive access to its Artificial Intelligence and Deep Learning capabilities. In addition, the Company and Inherent intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. An example of this development would be to expand Predictive's understanding of the genetics driving endometriosis by incorporating epigenetic data.


-2-


A joint scientific and medical advisory board is being established to assist in leveraging the platform assets of Predictive, Nebula, and Inherent. We are excited to have such accomplished individuals share in our commitment to bring personalized precision medicine to individuals, their physicians and healthcare stakeholders. The scientific and medical advisory board is expected to include the following individuals:


John Sorrentino, Chairman, Pfizer (retired) and Wyeth (formerly)
Michael Dey, Ph.D., Scientific Advisor, Wyeth (retired)
Nebula Genomics Representative
Michael Skinner, Ph.D., Scientific Advisor, Inherent Biosciences Representative
Hugh Taylor, M.D., Medical Advisor
Charles Andres, J.D., Ph.D., Greenberg Traurig (current) and Bristol-Myers Squibb (formerly)
Predictive Laboratories has previously disclosed that it has collected, acquired and in-licensed sample biobanks, proprietary disease databases, and a genealogical database. Predictive intends to utilize and enhance these platform assets through strategic collaboration and development agreements with Nebula Genomics and Inherent Biosciences. These collaborations expect to leverage the latest in low-cost clinical grade whole genome sequencing and genome analysis tools. Planned research will allow economic incentive for participants, DNA privacy through blockchain encryption, deep learning capabilities through artificial intelligence, and epigenetic and biomarker discovery activities focused initially on male and female infertility, obstetric and gynecologic diseases, and offspring health. These foundational platform technologies aim to deliver on the promise of precision medicine and informed drug discovery.
Although the first human genome was sequenced 20 years ago, the promise of precision medicine and the predictive power of our DNA has yet to be fully realized. Predictive is establishing a comprehensive database of genome sequences and epigenetic data coupled with other relevant patient information. Deep Learning Artificial Intelligence will be applied, as applicable, to these data with the intent of speeding development of new diagnostic and therapeutic opportunities. This platform is expected to provide a deeper understanding into disease and how disease uniquely impacts an individual.
Predictive has aligned with prominent experts in AI, genetics, epigenetics, diagnostics, and drug development. Predictive Analytics was formed to aggregate, leverage, and monetize genetic, epigenetic, genealogical and health data.


-3-


Predictive Analytics: The Foundation



[predpic001]
Data Input, Analysis and Execution
As a result of these strategic collaboration and development partnerships, planned commercial activities through Predictive Laboratories' CLIA diagnostic laboratory include the following:
· Contracted whole genome sequencing


· Genetic and epigenetic based diagnostics for women (including ArtGuide™, Fertility Dx™ and EndoRisk™), men and families.
Genomic sequences and epigenomic data, from properly consented individuals, can be analyzed by tools including the use of AI analysis.
Predictive Therapeutics intends to:
· Identify new drug targets with high efficiency
· Identify genomic inclusion/exclusion criteria for clinical trials
· Facilitate disease detection and develop potential clinical trial surrogate endpoints
· Establish data and research licensing agreements with pharmaceutical partners


Conclusions
Synergies are anticipated to allow Predictive Analytics the opportunity for advances in disease detection, prevention and drug development that could help to solve hard to detect and hard to treat diseases.


-4-


Safe Harbor Statement
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Predictive Technology Group, Inc.


Date: June 21, 2021
By:


/s/ Bradley Robinson
Bradley Robinson








Director /Chief Executive Officer
 

New member
Joined
Aug 5, 2020
Messages
30
Tokens
8K out - Item 8.01 Other Business Information
Business Update for Predictive Laboratories and Predictive Analytics
On May 7, 2021, the Company entered into a strategic development agreement (the "Agreement") with Nebula Genomics ("Nebula"). Under the terms of the Agreement, the Company may offer Nebula products to its customers, including 30x whole genome sequencing testing, analytical tools, and other products and services, which are fulfilled by Nebula. The Agreement includes a revenue sharing arrangement between the Company and Nebula.
Nebula has agreed to provide the Company with technologies and services to assist in Direct-To-Consumer ("DTC") and clinical diagnostic markets including privacy technologies, such as blockchain, and analytical tools. The Company and Nebula intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. These development activities are expected to be governed by joint scientific and medical advisory boards with representation from both companies.


On June 11, 2021, the Company entered into a strategic collaboration and development agreement (the "Inherent Agreement") with Inherent Biosciences, Inc. ("Inherent"). Under the terms of the Inherent Agreement, the Company may offer Inherent's commercial epigenetic based Sperm Biological Age product to its customers. Additionally, the Inherent Agreement contemplates the Company offering additional Inherent products as they become commercially available. These additional products may include:


Clinical Validation Phase
- Male Infertility Diagnostic (MFI)

Proof-of-Concept Phase
- Arthritis
- Premature Birth
- Autism (buccal swab parents/child)
- Autism (germline sperm)
- Hypospadias
- Fetal Heart Disease


Discovery Phase
- Developmental Abnormalities
- Endometriosis diagnostics
The Company and Inherent have revenue sharing provisions in the Inherent Agreement.
Inherent has agreed to provide Predictive access to its Artificial Intelligence and Deep Learning capabilities. In addition, the Company and Inherent intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. An example of this development would be to expand Predictive's understanding of the genetics driving endometriosis by incorporating epigenetic data.


-2-


A joint scientific and medical advisory board is being established to assist in leveraging the platform assets of Predictive, Nebula, and Inherent. We are excited to have such accomplished individuals share in our commitment to bring personalized precision medicine to individuals, their physicians and healthcare stakeholders. The scientific and medical advisory board is expected to include the following individuals:


John Sorrentino, Chairman, Pfizer (retired) and Wyeth (formerly)
Michael Dey, Ph.D., Scientific Advisor, Wyeth (retired)
Nebula Genomics Representative
Michael Skinner, Ph.D., Scientific Advisor, Inherent Biosciences Representative
Hugh Taylor, M.D., Medical Advisor
Charles Andres, J.D., Ph.D., Greenberg Traurig (current) and Bristol-Myers Squibb (formerly)
Predictive Laboratories has previously disclosed that it has collected, acquired and in-licensed sample biobanks, proprietary disease databases, and a genealogical database. Predictive intends to utilize and enhance these platform assets through strategic collaboration and development agreements with Nebula Genomics and Inherent Biosciences. These collaborations expect to leverage the latest in low-cost clinical grade whole genome sequencing and genome analysis tools. Planned research will allow economic incentive for participants, DNA privacy through blockchain encryption, deep learning capabilities through artificial intelligence, and epigenetic and biomarker discovery activities focused initially on male and female infertility, obstetric and gynecologic diseases, and offspring health. These foundational platform technologies aim to deliver on the promise of precision medicine and informed drug discovery.
Although the first human genome was sequenced 20 years ago, the promise of precision medicine and the predictive power of our DNA has yet to be fully realized. Predictive is establishing a comprehensive database of genome sequences and epigenetic data coupled with other relevant patient information. Deep Learning Artificial Intelligence will be applied, as applicable, to these data with the intent of speeding development of new diagnostic and therapeutic opportunities. This platform is expected to provide a deeper understanding into disease and how disease uniquely impacts an individual.
Predictive has aligned with prominent experts in AI, genetics, epigenetics, diagnostics, and drug development. Predictive Analytics was formed to aggregate, leverage, and monetize genetic, epigenetic, genealogical and health data.


-3-


Predictive Analytics: The Foundation



[predpic001]
Data Input, Analysis and Execution
As a result of these strategic collaboration and development partnerships, planned commercial activities through Predictive Laboratories' CLIA diagnostic laboratory include the following:
· Contracted whole genome sequencing


· Genetic and epigenetic based diagnostics for women (including ArtGuide™, Fertility Dx™ and EndoRisk™), men and families.
Genomic sequences and epigenomic data, from properly consented individuals, can be analyzed by tools including the use of AI analysis.
Predictive Therapeutics intends to:
· Identify new drug targets with high efficiency
· Identify genomic inclusion/exclusion criteria for clinical trials
· Facilitate disease detection and develop potential clinical trial surrogate endpoints
· Establish data and research licensing agreements with pharmaceutical partners


Conclusions
Synergies are anticipated to allow Predictive Analytics the opportunity for advances in disease detection, prevention and drug development that could help to solve hard to detect and hard to treat diseases.


-4-


Safe Harbor Statement
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Predictive Technology Group, Inc.


Date: June 21, 2021
By:


/s/ Bradley Robinson
Bradley Robinson








Director /Chief Executive Officer

Definitely positive, but will it move the needle?
 

Member
Joined
Jan 19, 2005
Messages
3,247
Tokens
ON 4/12 PREDS stock priced crossed over the long term simple movg avg
other then quick fake out, sell off before we finally got back on the pink sheets, the stock has been supported above it . Usually a very good sign that at least, the worse is over short term, and we can use that as a base to rally from I think the stock trades back into the 30's short term. one level at a time.....
 

Member
Joined
Jan 19, 2005
Messages
3,247
Tokens
6ea51bdc-72a7-42aa-a967-aef0cf415036.png
Predictive Tech Group PRED~ .34 (fully reporting/current)


We continue to recommend PRED as our 2021 stock pick. Geared toward risk/reward
strategy containing severely undervalued and heavily discounted assets and huge
revenue potential. Company is a therapeutics and life science company. There are 3 divisions: PRED Analytics, Laboratories and Biotech.


Collaboration: Thermo Fisher (TMO)~$32B in rev, illumina (ILMN)~ $3.2B , BGI Genomics
( 300676 ~Shenzhen exchange)~$8.3B, Nebula Genomics (private- whole genomic sequencing-better than 23&ME and
Ancestry)+Dr George Church~known as Father of synthetic biology, Inherent Biosciences (private-developer of genetic test for Autism from male sperm genetic marker.
Late stage before commercialization for Endometriosis Test ( market $2B). Infertility
treatment market $2B in 2020, globally $14.2B. Their late stage commercialization~ ARTguide. Stem Cell Therapy market
worldwide $14.8 billion. FDA has banned most Stem Cell sales so PRED may reach for
International markets ( we assume China ). Global DNA sequencing market accounts for $8.4B in 2020,~ projected $40B by 2030 (Nebula, Inherent, BGI, PRED playing ).
PRED has 300k DNA samples with serious maternal and neonatal disorder (believed to be
the largest library in the world~valued @ $300/sample, of that 45k ( Total sequenced DNA Strands valued @ $1000.00/sample). Hidden $120M!


Management, BOD & Advisory Board reads like a Fortune 100 company. The company
holds at least 35-40 valued patents, a world class CLIA/CAP lab and numerous filings with the FDA & more intended be to filed during fiscal 2022
beginning July 1, 2021.( granted patents~ June 1, 2021~ treating scoliosis, April 22, 2021
granted using genetic markers associated with endometriosis).


PRED weathered listing difficulties/ Covid and in our opinion is on the fast track for rapid
expansion of their "field of dreams". We still remain and continue to rate PRED with a strong speculative buy rating at current levels for extra-ordinary gains.



Note:Investing is about patience and believing and averaging down if you still believe!
Jan 1, 2021 PRED was .06! For some that initiated a position and for those that aggressively averaged down~you have profited and or nearing break even. We anticipate
a continued "climb a wall of worry"!



 

Member
Joined
Jan 19, 2005
Messages
3,247
Tokens
RAFA audit had been delayed for a few weeks ( positive reasons I hear ) There are many funds that will buy once this audit process is over . RAFA will be not home run, but a grand slam

Accumulate and get positioned while you can
 

Member
Joined
Jan 13, 2010
Messages
113
Tokens
When i search Rafa to buy the stock it only comes up as APKN:US, Rafarma Pharmaceuticals. But theres no value to this stock. Any idea why i dont see RAFA
 

Member
Joined
Jan 13, 2010
Messages
113
Tokens
I can find any of your other ones but not rafa. Pred, gtii they all show. Rafa only shows as the one i said above. Not sure what I'm doing wrong
 

Member
Joined
Jan 19, 2005
Messages
3,247
Tokens
[h=2]OTC Markets | Official site of OTCQX, OTCQB and Pink Markets[/h]https://www.otcmarkets.com/stock/RAFA/security
Feb 01, 2020 · Symbol change from APKN to RAFA: More . Displaying 1 of 1 Actions. Dividends & Splits. Dividends. Splits. No dividends. Short Selling Data. Short Interest. 335 (-97.56%) 02/12/2021. Significant Failures to Deliver. No. Security Notes. Capital Change=shs decreased by 1 for 5 split. Pay-date=6-30-96
 

Member
Joined
Jan 19, 2005
Messages
3,247
Tokens
For those of you in Rafa , Im changing my target this year to 4-6 bucks . My confidence level is even higher now regarding the stock, but Covid has hurt the timing .

International travel and the auditing process specifically .

Lets target NASDAQ by Jan . and double digits in 2022. 15, 20, more????

Very limited downside here at this price near 1.50 .
 

Member
Joined
Dec 13, 2007
Messages
11,076
Tokens
For those of you in Rafa , Im changing my target this year to 4-6 bucks . My confidence level is even higher now regarding the stock, but Covid has hurt the timing .

International travel and the auditing process specifically .

Lets target NASDAQ by Jan . and double digits in 2022. 15, 20, more????

Very limited downside here at this price near 1.50 .


I'm getting more interested the more I read.. Covids to blame for a lot of missed endpoints in Pharma this year.
 

Forum statistics

Threads
1,106,787
Messages
13,439,000
Members
99,339
Latest member
billcunninghamhomeloans
The RX is the sports betting industry's leading information portal for bonuses, picks, and sportsbook reviews. Find the best deals offered by a sportsbook in your state and browse our free picks section.FacebookTwitterInstagramContact Usforum@therx.com